Erratum: Molecular epidemiology of human liver cancer: Insights into etiology, pathogenesis and prevention from The Gambia, West Africa (Carcinogenesis vol. 27 (10) 10.1093/carcin/bgl060);Molecular epidemiology of human liver cancer: Insights into etiology, pathogenesis and prevention from The Gambia, West Africa

Carcinogenesis

Volumn 27, Issue 10, 2006, Pages 2070-2082

  Kirk, Gregory D ^a   Bah, Ebrima ^b   Montesano, Ruggero ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; BIOLOGICAL MARKER; GLUTATHIONE TRANSFERASE M1; HEPATITIS B VACCINE; HEPATITIS C VACCINE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN P53;

ALCOHOL CONSUMPTION; ASPERGILLUS FLAVUS; CANCER INCIDENCE; CANCER RESEARCH; CARCINOGENESIS; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; FATTY LIVER; FEMALE; FOOD CONTAMINATION; FOOD QUALITY; FOOD STORAGE; GAMBIA; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON OVERLOAD; LIVER CANCER; LIVER CELL CARCINOMA; MALE; MOLECULAR EPIDEMIOLOGY; OBESITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 33749558598     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl226     Document Type: Erratum

References (137)

1. Parkin,D.M., Bray,F.I and Devesa,S.S. (2001) Cancer burden in the year 2000. The global picture. Eur. J. Cancer, 37 (suppl. 8), S4-66.
2. Bah,E., Parkin,D.M., Hall,A.J., Jack,A.D and Whittle,H. (2001) Cancer in The Gambia: 1988-97. Br. J. Cancer, 84, 1207-1214.
3. Whittle,H., Inskip,H., Bradley,A.K., McLaughlan,K., Shenton,F., Lamb,W., Eccles,J., Baker,B.A and Hall,A.J. (1990) The pattern of childhood hepatitis B infection in two Gambian villages. J. Infect. Dis., 161, 1112-1115.
4. Whittle,H.C., Bradley,A.K., McLauchlan,K., Ajdukiewicz,A.B., Howard,C.R., Zuckerman,A.J and McGregor,I.A. (1983) Hepatitis B virus infection in two Gambian villages. Lancet, 1, 1203-1206.
5. Mendy,M.E., Whittle,H.C., O'Donovan,D and Kekule,A.S. (1998) Prevalence of hepatitis C and GB virus infection in The Gambia. Br. J. Biomed. Sci., 55, 92-93.
6. Wild,C.P., Fortuin,M., Donato,F., Whittle,H.C., Hall,A.J., Wolf,C.R and Montesano,R. (1993) Aflatoxin, liver enzymes, and hepatitis B virus infection in Gambian children. Cancer Epidemiol. Biomarkers Prev., 2, 555-561.
7. Wild,C.P., Hudson,G.J., Sabbioni,G., Chapot,B., Hall,A.J., Wogan,G.N., Whittle,H., Montesano,R and Groopman,J.D. (1992) Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol. Biomarkers Prev., 1, 229-234.
8. GHIS (1987) The Gambia Hepatitis Intervention Study. The Gambia Hepatitis Study Group. Cancer Res., 47, 5782-5787.
9. Kirk,G.D., Lesi,O.A., Mendy,M., Akano,A.O., Sam,O., Goedert,J.J., Hainaut,P., Hall,A.J., Whittle,H and Montesano,R. (2004) The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology, 39, 211-219.
10. Ryder,R.W., Whittle,H.C., Sanneh,A.B., Ajdukiewicz,A.B., Tulloch,S and Yvonnet,B. (1992) Persistent hepatitis B virus infection and hepatoma in The Gambia, West Africa. A case-control study of 140 adults and their 603 family contacts. Am. J. Epidemiol., 136, 1122-1131.
11. Bah,E., Hall,A.J and Inskip,H.M. (1990) The first 2 years of The Gambian National Cancer Registry. Br. J. Cancer, 62, 647-650.
12. Pisani,P., Parkin,D.M., Munoz,N and Ferlay,J. (1997) Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev., 6, 387-400.
13. Vall Mayans,M., Hall,A.J., Inskip,H.M., Chotard,J., Lindsay,S.W., Coromina,E., Mendy,M., Alonso,P.L and Whittle,H. (1990) Risk factors for transmission of hepatitis B virus to Gambian children. Lancet, 336, 1107-1109.
14. Martinson,F.E., Weigle,K.A., Royce,R.A., Weber,D.J., Suchindran,C.M and Lemon,S.M. (1998) Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am. J. Epidemiol., 147, 478-487.
15. Mayans,M.V., Hall,A.J., Inskip,H.M., Lindsay,S.W., Chotard,J., Mendy,M and Whittle,H.C. (1994) Do bedbugs transmit hepatitis B? Lancet, 343, 761-763.
16. Edmunds,W.J., Medley,G.F., Nokes,D.J., Hall,A.J and Whittle,H.C. (1993) The influence of age on the development of the hepatitis B carrier state. Proc. Biol. Sci., 253, 197-201.
17. Edmunds,W.J., Medley,G.F., Nokes,D.J., O'Callaghan,C.J., Whittle,H.C and Hall,A.J. (1996) Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol. Infect., 117, 313-325.
18. Mendy,M.E., Fortuin,M., Hall,A.J., Jack,A.D and Whittle,H.C. (1999) Hepatitis B virus DNA in relation to duration of hepatitis B surface antigen carriage. Br. J. Biomed. Sci., 56, 34-38.
19. Evans,A.A., O'Connell,A.P., Pugh,J.C., Mason,W.S., Shen,F.M., Chen,G.C., Lin,W.Y., Dia,A., M'Boup,S., Drame,B and London,W.T. (1998) Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev., 7, 559-565.
20. Chen,C.J., Yang,H.I., Su,J., Jen,C.L., You,S.L., Lu,S.N., Huang,G.T and Iloeje,U.H. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 295, 65-73.
21. Tsai,J.F., Jeng,J.E., Ho,M.S., Chang,W.Y., Hsieh,M.Y., Lin,Z.Y and Tsai,J.H. (1996) Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br. J. Cancer, 73, 1498-1502.
22. Ishikawa,T., Ichida,T., Yamagiwa,S., Sugahara,S., Uehara,K., Okoshi,S and Asakura,H. (2001) High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J. Gastroenterol. Hepatol., 16, 1274-1281.
23. Liang,T.J and Ghany,M. (2002) Hepatitis B e Antigen - the dangerous endgame of hepatitis B. N. Engl. J. Med., 347, 208-210.
24. Yang,H.I., Lu,S.N., Liaw,Y.F., You,S.L., Sun,C.A., Wang,L.Y., Hsiao,C.K., Chen,P.J., Chen,D.S and Chen,C.J. (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med., 347, 168-174.
25. Yu,M.W., Yeh,S.H., Chen,P.J., Liaw,Y.F., Lin,C.L., Liu,C.J., Shih,W.L., Kao,J.H., Chen,D.S and Chen,C.J. (2005) Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J. Natl Cancer Inst., 97, 265-272.
26. Norder,H., Courouce,A.M., Coursaget,P., Echevarria,J.M., Lee,S.D., Mushahwar,I.K., Robertson,B.H., Locarnini,S and Magnius,L.O. (2004) Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology, 47, 289-309.
27. Chu,C.J., Keeffe,E.B., Han,S.H et al. (2003) Hepatitis B virus genotypes in the United States: Results of a nationwide study. Gastroenterology, 125, 444-451.
28. Chu,C.J and Lok,A.S. (2002) Clinical significance of hepatitis B virus genotypes. Hepatology, 35, 1274-1276.
29. Kao,J.H and Chen,D.S. (2002) Global control of hepatitis B virus infection. Lancet Infect. Dis., 2, 395-403.
30. Chan,H.L., Hui,A.Y., Wong,M.L., Tse,A.M., Hung,L.C., Wong,V.W and Sung,J.J. (2004) Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-1498.
31. Kew,M.C., Kramvis,A., Yu,M.C., Arakawa,K and Hodkinson,J. (2005) Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-Saharan Africans. J. Med. Virol., 75, 513-521.
32. Orito,E. and Mizokami,M. (2003) Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Intervirology, 46, 408-412.
33. Kramvis,A., Bukofzer,S., Kew,M.C and Song,E. (1997) Nucleic acid sequence analysis of the precore region of hepatitis B virus from sera of southern African black adult carriers of the virus. Hepatology, 25, 235-240.
34. Kramvis,A., Kew,M.C and Bukofzer,S. (1998) Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma. J. Hepatol., 28, 132-141.
35. Baptista,M., Kramvis,A and Kew,M.C. (1999) High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology, 29, 946-953.
36. Kuang,S.Y., Jackson,P.E., Wang,J.B., Lu,P.X., Munoz,A., Qian,G.S., Kensler,T.W and Groopman,J.D. (2004) Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc. Natl Acad. Sci. USA, 101, 3575-3580.
37. Kuang,S.Y., Lekawanvijit,S., Maneekarn,N., Thongsawat,S., Brodovicz,K., Nelson,K and Groopman,J.D. (2005) Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol. Biomarkers Prev., 14, 380-384.
38. Dumpis,U., Mendy,M., Hill,A., Thursz,M., Hall,A., Whittle,H and Karayiannis,P. (2001) Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. J. Med. Virol., 65, 664-670.
39. Madhava,V., Burgess,C and Drucker,E. (2002) Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect. Dis., 2, 293-302.
40. WHO (1999) Global surveillance, control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral. Hepat., 6, 35-47.
41. Frank,C., Mohamed,M.K., Strickland,G.T et al. (2000) The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet, 355, 887-891.
42. Zhang,M., Sun,X.D., Mark,S.D., Chen,W., Wong,L., Dawsey,S.M., Qiao,Y.L., Fraumeni,J.F,Jr, Taylor,P.R. and O'Brien,T.R. (2005) Hepatitis C virus infection, Linxian, China. Emerg. Infect. Dis., 11, 17-21.
43. Simonsen,L., Kane,A., Lloyd,J., Zaffran,M and Kane,M. (1999) Unsafe injections in the developing world and transmission of bloodborne pathogens: A review. Bull World Health Organ., 77, 789-800.
44. Drucker,E., Alcabes,P.G and Marx,P.A. (2001) The injection century: massive unsterile injections and the emergence of human pathogens. Lancet, 358, 1989-1992.
45. Kane,M. (1998) Unsafe injections. Bull World Health Organ., 76, 99-100.
46. Sulkowski,M.S., Ray,S.C and Thomas,D.L. (2002) Needlestick transmission of hepatitis C. JAMA, 287, 2406-2413.
47. Wild,C.P., Yin,F., Turner,P.C., Chemin,I., Chapot,B., Mendy,M., Whittle,H., Kirk,G.D and Hall,A.J. (2000) Environmental and genetic determinants of aflatoxin-albumin adducts in The Gambia. Int. J. Cancer, 86, 1-7.
48. IARC (1993) Some naturally occurring substances: Food items and constituents, heterocyclic amines and mycotoxins. Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 56, International Agency for Research on Cancer, Lyon.
49. Wogan,G.N (2000) Impacts of chemicals on liver cancer risk. Semin. Cancer Biol., 10, 201-210.
50. Wogan,G.N (1999) Aflatoxin as a human carcinogen. Hepatology, 30, 573-575.
51. Jackson,P.E and Groopman,J.D. (1999) Aflatoxin and liver cancer. Baillieres Best Pract. Res. Clin. Gastroenterol., 13, 545-555.
52. Wild,C.P., Jiang,Y.Z., Allen,S.J., Jansen,L.A., Hall,A.J and Montesano,R. (1990) Aflatoxin-albumin adducts in human sera from different regions of the world. Carcinogenesis, 11, 2271-2274.
53. Wild,C.P., Jansen,L.A., Cova,L and Montesano,R. (1993) Molecular dosimetry of aflatoxin exposure: Contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ. Health Perspect., 99, 115-122.
54. Groopman,J.D. (1994) Molecular dosimetry methods for assessing human aflatoxin exposures. In Eaton,D. and Groopman,J.D. (eds) The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance. Academic Press, Inc., San Diego, CA, pp. 259-279.
55. Groopman,J.D., Cain,L.G and Kensler,T.W. (1988) Aflatoxin exposure in human populations: Measurements and relationship to cancer. Crit. Rev. Toxicol., 19, 113-145.
56. Sabbioni,G., Skipper,P.L., Buchi,G and Tannenbaum,S.R. (1987) Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis, 8, 819-824.
57. Garner,R.C., Dvorackova,I and Tursi,F. (1988) Immunoassay procedures to detect exposure to aflatoxin B1 and benzo(a)pyrene in animals and man at the DNA level. Int. Arch. Occup. Environ. Health, 60, 145-150.
58. Wild,C.P., Garner,R.C., Montesano,R and Tursi,F. (1986) Aflatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis, 7, 853-858.
59. Sizaret,P., Malaveille,C., Montesano,R and Frayssinet,C. (1982) Detection of aflatoxins and related metabolites by radioimmunoassay. J. Natl Cancer Inst., 69, 1375-1381.
60. Turner,P.C., Mendy,M., Whittle,H., Fortuin,M., Hall,A.J and Wild,C.P. (2000) Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop. Med. Int. Health, 5, 837-841.
61. Montesano,R., Hainaut,P and Wild,C.P. (1997) Hepatocellular carcinoma: from gene to public health. J. Natl Cancer Inst., 89, 1844-1851.
62. Wild,C.P., Rasheed,F.N., Jawla,M.F., Hall,A.J., Jansen,L.A and Montesano,R. (1991) In-utero exposure to aflatoxin in west Africa. Lancet, 337, 1602.
63. Zarba,A., Wild,C.P., Hall,A.J., Montesano,R., Hudson,G.J and Groopman,J.D. (1992) Aflatoxin M1 in human breast milk from The Gambia, West Africa, quantified by combined monoclonal antibody immunoaffinity chromatography and HPLC. Carcinogenesis, 13, 891-894.
64. Wild,C.P., Pionneau,F.A., Montesano,R., Mutiro,C.F and Chetsanga,C.J. (1987) Aflatoxin detected in human breast milk by immunoassay. Int. J. Cancer, 40, 328-333.
65. Gong,Y.Y., Cardwell,K., Hounsa,A., Egal,S., Turner,P.C., Hall,A.J and Wild,C.P. (2002) Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: Cross sectional study. BMJ, 325, 20-21.
66. Turner,P.C., Moore,S.E., Hall,A.J., Prentice,A.M and Wild,C.P. (2003) Modification of immune function through exposure to dietary aflatoxin in Gambian children. Environ. Health Perspect., 111, 217-220.
67. Wild,C.P., Shrestha,S.M., Anwar,W.A and Montesano,R. (1992) Field studies of aflatoxin exposure, metabolism and induction of genetic alterations in relation to HBV infection and hepatocellular carcinoma in The Gambia and Thailand. Toxicol Lett., 64-65, 455-461.
68. Kenya,C. (2004) Outbreak of aflatoxin poisoning - eastern and central provinces, Kenya, January-July 2004. MMWR Morb. Mortal. Wkly Rep., 53, 790-793.
69. Hsu,I.C., Metcalf,R.A., Sun,T., Welsh,J.A., Wang,N.J and Harris,C.C. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-428.
70. Bressac,B., Kew,M., Wands,J and Ozturk,M. (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 350, 429-431.
71. Stern,M.C., Umbach,D.M., Yu,M.C., London,S.J., Zhang,Z.Q and Taylor,J.A. (2001) Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol. Biomarkers Prev., 10, 617-625.
72. Smela,M.E., Currier,S.S., Bailey,E.A and Essigmann,J.M. (2001) The chemistry and biology of aflatoxin B(1): From mutational spectrometry to carcinogenesis. Carcinogenesis, 22, 535-545.
73. Smela,M.E., Hamm,M.L., Henderson,P.T., Harris,C.M., Harris,T.M and Essigmann,J.M. (2002) The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc. Natl Acad. Sci. USA, 99, 6655-6660.
74. Wild,C.P., Law,G.R and Roman,E. (2002) Molecular epidemiology and cancer: Promising areas for future research in the post-genomic era. Mutat. Res., 499, 3-12.
75. Hainaut,P. and Hollstein,M. (2000) p53 and human cancer: The first ten thousand mutations. Adv. Cancer Res., 77, 81-137.
76. Kirk,G.D., Camus-Randon,A.M., Mendy,M., Goedert,J.J., Merle,P., Trepo,C., Brechot,C., Hainaut,P and Montesano,R. (2000) Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J. Natl Cancer Inst., 92, 148-153.
77. Szymanska,K., Lesi,O.A., Kirk,G.D et al. (2004) Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in The Gambia, West Africa. Int. J. Cancer, 110, 374-379.
78. Kirk,G.D., Lesi,O.A., Mendy,M., Szymanska,K., Whittle,H., Goedert,J.J., Hainaut,P and Montesano,R. (2005) 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene, 24, 5858-5867.
79. Huang,X.H., Sun,L.H., Lu,D.D., Sun,Y., Ma,L.J., Zhang,X.R., Huang,J and Yu,L. (2003) Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China. World J. Gastroenterol., 9, 692-695.
80. Kimbi,G.C., Kew,M.C., Yu,M.C., Arakawa,K and Hodkinson,J. (2005) 249ser p53 mutation in the serum of black southern African patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol., 20, 1185-1190.
81. Dong-Dong,L. and Xi-Ran,Z. (2003) Plasma 249Ser p53 mutation in patients with hepatocellular carcinoma residing in a high risk area. J. Cell. Mol. Med., 7, 89-92.
82. Jackson,P.E., Qian,G.S., Friesen,M.D., Zhu,Y.R., Lu,P., Wang,J.B., Wu,Y., Kensler,T.W., Vogelstein,B and Groopman,J.D. (2001) Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res., 61, 33-35.
83. Aguilar,F., Harris,C.C., Sun,T., Hollstein,M and Cerutti,P. (1994) Geographic variation of p53 mutational profile in nonmalignant human liver. Science, 264, 1317-1319.
84. Jackson,P.E., Kuang,S.Y., Wang,J.B., Strickland,P.T., Munoz,A., Kensler,T.W., Qian,G.S and Groopman,J.D. (2003) Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis, 24, 1657-1663.
85. Turner,P.C., Sylla,A., Kuang,S.Y., Marchant,C.L., Diallo,M.S., Hall,A.J., Groopman,J.D and Wild,C.P. (2005) Absence of TP53 codon 249 mutations in young Guinean children with high aflatoxin exposure. Cancer Epidemiol. Biomarkers Prev., 14, 2053-2055.
86. Lleonart,M.E., Kirk,G.D., Villar,S et al. (2005) Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol. Biomarkers Prev., 14, 2956-2962.
87. Brechot,C. (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms. Gastroenterology, 127, S56-61.
88. Brechot,C., Gozuacik,D., Murakami,Y and Paterlini-Brechot,P. (2000) Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin. Cancer Biol., 10, 211-231.
89. Chu,C.M (2000) Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol., 15 (suppl), E25-30.
90. Liang,T.J and Heller,T. (2004) Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology, 127, S62-71.
91. Donato,F., Boffetta,P and Puoti,M. (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer, 75, 347-354.
92. Zarski,J.P., Bohn,B., Bastie,A., Pawlotsky,J.M., Baud,M., Bost-Bezeaux,F., Tran van Nhieu,J., Seigneurin,J.M., Buffet,C and Dhumeaux,D. (1998) Characteristics of patients with dual infection by hepatitis B and C viruses. J. Hepatol., 28, 27-33.
93. Torbenson,M. and Thomas,D.L. (2002) Occult hepatitis B. Lancet Infect. Dis., 2, 479-486.
94. Ming,L., Thorgeirsson,S.S., Gail,M.H et al. (2002) Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology, 36, 1214-1220.
95. Sell,S. (2003) Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res., 63, 7553-7562.
96. Qian,G.S., Ross,R.K., Yu,M.C., Yuan,J.M., Gao,Y.T., Henderson,B.E., Wogan,G.N and Groopman,J.D. (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 3, 3-10.
97. Ross,R.K., Yuan,J.M., Yu,M.C., Wogan,G.N., Qian,G.S., Tu,J.T., Groopman,J.D., Gao,Y.T and Henderson,B.E. (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339, 943-946.
98. Kew,M.C (2003) Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int., 23, 405-409.
99. Kirk,G.D., Turner,P.C., Gong,Y et al. (2005) Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol. Biomarkers Prev., 14, 373-379.
100. Lunn,R.M., Langlois,R.G., Hsieh,L.L., Thompson,C.L and Bell,D.A. (1999) XRCC1 polymorphisms: Effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res., 59, 2557-2561.
101. Yu,M.W., Chiu,Y.H., Chiang,Y.C., Chen,C.H., Lee,T.H., Santella,R.M., Chern,H.D., Liaw,Y.F and Chen,C.J. (1999) Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: Independent and interactive effects. Am. J. Epidemiol., 149, 621-629.
102. Bian,J.C., Shen,F.M., Shen,L., Wang,T.R., Wang,X.H., Chen,G.C and Wang,J.B. (2000) Susceptibility to hepatocellular carcinoma associated with null genotypes of GSTM1 and GSTT1. World J. Gastroenterol., 6, 228-230.
103. Yu,M.W., Yang,S.Y., Pan,I.J., Lin,C.L., Liu,C.J., Liaw,Y.F., Lin,S.M., Chen,P.J., Lee,S.D and Chen,C.J. (2003) Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J. Natl Cancer Inst., 95, 1485-1488.
104. O'Brien,T.R., Kirk,G and Zhang,M. (2004) Hepatocellular carcinoma: paradigm of preventive oncology. Cancer J., 10, 67-73.
105. BBC (2005) Cervical cancer jab in two years.
106. Beasley,R.P., Hwang,L.Y., Lin,C.C and Chien,C.S. (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet, 2, 1129-1133.
107. Blumberg,B.S and London,W.T. (1982) Hepatitis B virus: Pathogenesis and prevention of primary cancer of the liver. Cancer, 50, 2657-2665.
108. Muraskin,W. (1995) The War Against Hepatitis B. University of Pennsylvania Press, Philadelphia, PA.
109. Viviani,S., Jack,A., Hall,A.J., Maine,N., Mendy,M., Montesano,R and Whittle,H.C. (1999) Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine, 17, 2946-2950.
110. Fortuin,M., Chotard,J., Jack,A.D., Maine,N.P., Mendy,M., Hall,A.J., Inskip,H.M., George,M.O and Whittle,H.C. (1993) Efficacy of hepatitis B vaccine in The Gambian expanded programme on immunisation. Lancet, 341, 1129-1131.
111. Whittle,H.C., Lamb,W.H and Ryder,R.W. (1987) Trials of intradermal hepatitis B vaccines in Gambian children. Ann. Trop. Paediatr., 7, 6-9.
112. Whittle,H., Jaffar,S., Wansbrough,M., Mendy,M., Dumpis,U., Collinson,A and Hall,A. (2002) Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ, 325, 569.
113. Kane,M.A and Brooks,A. (2002) New immunization initiatives and progress toward the global control of hepatitis B. Curr. Opin. Infect. Dis., 15, 465-469.
114. Chen,H.L., Chang,M.H., Ni,Y.H., Hsu,H.Y., Lee,P.I., Lee,C.Y and Chen,D.S. (1996) Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA, 276, 906-908.
115. Sun,Z., Ming,L., Zhu,X and Lu,J. (2002) Prevention and control of hepatitis B in China. J. Med. Virol., 67, 447-450.
116. Chang,M.H., Chen,C.J., Lai,M.S., Hsu,H.M., Wu,T.C., Kong,M.S., Liang,D.C., Shau,W.Y and Chen,D.S. (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med., 336, 1855-1859.
117. Chang,M.H., Shau,W.Y., Chen,C.J., Wu,T.C., Kong,M.S., Liang,D.C., Hsu,H.M., Chen,H.L., Hsu,H.Y and Chen,D.S. (2000) Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA, 284, 3040-3042.
118. Kirk,G.D (2003) Hepatitis B vaccination and liver cancer. In Stewart,B.W. and Kleihues,P. (eds) World Cancer Report. IARC Press, Lyon, pp. 144-147.
119. Jack,A.D., Hall,A.J., Maine,N., Mendy,M and Whittle,H.C. (1999) What level of hepatitis B antibody is protective? J. Infect. Dis., 179, 489-492.
120. Liao,S.S., Li,R.C., Li,H., Yang,J.Y., Zeng,X.J., Gong,J., Wang,S.S., Li,Y.P and Zhang,K.L. (1999) Long-term efficacy of plasma-derived hepatitis B vaccine: A 15-year follow-up study among Chinese children. Vaccine, 17, 2661-2666.
121. Lin,Y.C., Chang,M.H., Ni,Y.H., Hsu,H.Y and Chen,D.S. (2003) Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J. Infect. Dis., 187, 134-138.
122. Wu,J.S., Hwang,L.Y., Goodman,K.J and Beasley,R.P. (1999) Hepatitis B vaccination in high-risk infants: 10-year follow-up. J. Infect. Dis., 179, 1319-1325.
123. Fortuin,M., Karthigesu,V., Allison,L., Howard,C., Hoare,S., Mendy,M and Whittle,H.C. (1994) Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J. Infect. Dis., 169, 1374-1376.
124. Karthigesu,V.D., Allison,L.M., Fortuin,M., Mendy,M., Whittle,H.C and Howard,C.R. (1994) A novel hepatitis B virus variant in the sera of immunized children. J. Gen. Virol., 75, 443-448.
125. Soussan,P., Pol,S., Garreau,F., Brechot,C and Kremsdorf,D. (2001) Vaccination of chronic hepatitis B virus carriers with preS2/S envelope protein is not associated with the emergence of envelope escape mutants. J. Gen. Virol., 82, 367-371.
126. Hsu,H.Y., Chang,M.H., Ni,Y.H and Chen,H.L. (2004) Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut, 53, 1499-1503.
127. Zuckerman,J.N and Zuckerman,A.J. (2003) Mutations of the surface protein of hepatitis B virus. Antiviral Res., 60, 75-78.
128. Wild,C.P and Hall,A.J. (2000) Primary prevention of hepatocellular carcinoma in developing countries. Mutat. Res., 462, 381-393.
129. Carlson,M.A., Bargeron,C.B., Benson,R.C., Fraser,A.B., Phillips,T.E., Velky,J.T., Groopman,J.D., Strickland,P.T and Ko,H.W. (2000) An automated, handheld biosensor for aflatoxin. Biosens. Bioelectron., 14, 841-848.
130. Kensler,T.W., Egner,P.A., Wang,J.B et al. (2004) Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology, 127, S310-8.
131. Kensler,T.W., Groopman,J.D and Roebuck,B.D. (1998) Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man. Mutat. Res., 402, 165-172.
132. Kensler,T.W., Egner,P.A., Wang,J.B et al. (2002) Strategies for chemoprevention of liver cancer. Eur. J. Cancer Prev., 11 (suppl. 2), S58-64.
133. Turner,P.C., Sylla,A., Gong,Y.Y., Diallo,M.S., Sutcliffe,A.E., Hall,A.J and Wild,C.P. (2005) Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: A community-based intervention study. Lancet, 365, 1950-1956.
134. Hall,A.J., Roberston,R.L., Crivelli,P.E., Lowe,Y., Inskip,H., Snow,S.K. and Whittle,H. (1993) Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans. R Soc. Trop. Med. Hyg., 87, 333-336.
135. Hall,A.J and Smith,P.G. (1999) Prevention of hepatocellular cancer: One of the most cost-effective ways to reduce adult mortality? Br. J. Cancer, 81, 1097-1098.
136. Hall,A. (1998) We have a cancer vaccine - why don't we use it? Trop. Med. Int. Health, 3, 337-338.
137. Hussain,S.P and Harris,C.C. (1998) Molecular epidemiology of human cancer. Toxicol. Lett., 102-103, 219-225.